Trials / Active Not Recruiting
Active Not RecruitingNCT06355531
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 241 (actual)
- Sponsor
- Ferrer Internacional S.A. · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FNP-223 | Oral tablets |
| DRUG | Placebo | Oral tablets |
Timeline
- Start date
- 2024-07-23
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
- First posted
- 2024-04-09
- Last updated
- 2025-10-15
Locations
44 sites across 9 countries: United States, France, Germany, Hungary, Italy, Poland, Portugal, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06355531. Inclusion in this directory is not an endorsement.